Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Balloon entrapment in valvuloplasty can be life-threatening, especially after balloon rupture. Learn about a new technique involving balloon internalisation and safety snares for successful retrieval and sheath upsizing.

The European Bifurcation Club Left Main (EBC MAIN) trial addressed the issue of provisional single stent versus upfront double stenting in 467 patients with true bifurcation distal left main disease. 

So far, only one other randomized trial, DKCRUSH-V (n=482), has addressed the same research question, showing better...

Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.

The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...

Aaysha Cader provides her take on the ECLIPSE trial presented by Gregg W. Stone at ACC.25 in Chicago.

Intravascular imaging is a cornerstone of invasive management of coronary disease, requiring specialized training to interpret either IVUS or OCT. AI can facilitate interpretation by non-specialists in real time.

Alex Sticchi provides his take on the 5-year outcomes from PARTNER 3 Low Risk which were presented by Martin B. Leon at TCT Congress 2023.

Nicola Ryan provides her take on the ALIGN AR trial which was presented by Vinod H. Thourani at TCT Congress 2023. The Align AR trial is a prospective single-arm investigation device exemption study assessing the safety and efficacy of the Trilogy transcatheter heart valve system in patients with...

In collaboration with EuroIntervention Journal

The authors decided to create a survey tailored for ICTs in order to assess the changes in their training. Capturing the essence of the responses may help to identify the most appropriate strategies to provide the highest standards and skills achievements in COVID-19...

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.